Studies in other cancers have reported similar results; high expression of SNHG3 was found to be significantly associated with poor prognosis in gastric cancer (30), osteosarcoma (31), laryngeal carcinoma (32), non-small-cell lung cancer (33), and colorectal cancer (34). Here, SNHG3 is linked to non-small cell lung carcinoma.